普华和顺(01358.HK)中期溢利增长54.9%至5990万元
格隆汇8月28日丨普华和顺(01358.HK)公布,截至2019年6月30日止6个月,公司来自持续经营业务的收入1.72亿元人民币,同比增长20.5%;来自持续经营业务毛利1.07亿元,同比增长21.4%;期间溢利5990万元,同比增长54.9%;每股盈利3.82分。
收入增长乃由于持续经营业务中输液器业务销售额增长所致。该增长主要由于:(i)输液器销量增长;及(ii)一次性静脉留置针销售额增加人民币8.5百万元所致。
作为开发创新产品的行业领先者,该集团拥有一支由经验丰富的成员组成的研发团队。该团队与护理专家、医院(尤其是三甲医院)、一流大学研究中心及其他研究机构密切合作。截至2019年6月30日止,该集团已拥有68项高端输液器产品专利,并已申请11项新专利。该集团将继续投资产品创新及研发,以力求维持其于业内的领先地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.